Timolol Compositions for Glaucoma Treatment, Novaliq

USPTO granted patent US12599607B2 to Novaliq GmbH on April 14, 2026. The patent covers pharmaceutical compositions comprising the beta-1 receptor blocker timolol in a semifluorinated alkane vehicle for ophthalmic topical administration. The 21-claim patent specifically addresses compositions for treating glaucoma, increased intraocular pressure, ocular hypertension, and related symptoms.

This patent grant establishes enforceable intellectual property rights for Novaliq, preventing competitors from making, using, or selling the claimed timolol-semifluorinated alkane compositions in the United States without authorization. Pharmaceutical companies developing competing ophthalmic beta-blocker formulations for glaucoma treatment may need to design around these claims or pursue licensing arrangements.